The role of platelets in the regulation of myeloid-derived suppressor cells in immune thrombocytopenia.

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immune regulatory cells that play crucial roles in suppressing immune responses and promoting immune tolerance in autoimmune diseases. Platelets, historically recognized for their role in hemostasis, have recently attracted significant attention for their immune regulatory functions, mainly through their interactions with immune cells, including MDSCs. In patients with immune thrombocytopenia (ITP), both the quantity and suppressive function of MDSCs are decreased. However, following treatment and subsequent elevation of platelet counts, the mean level and suppressive capacity of MDSCs increase. Studies have indicated that platelet-derived products can increase the suppressive capacity of MDSCs in ITP, thereby promoting immune tolerance and reducing inflammation. Conversely, specific platelet-secreted molecules such as TGF-β and histamine play complex roles and are capable of both augmenting and inhibiting MDSC activity, depending on the context. Understanding these interactions reveals potential targets in platelet-MDSC signaling pathways as novel approaches for ITP management. Future research could investigate targeted therapies that modulate MDSC function by enhancing or inhibiting specific platelet-derived mediators, leading to the development of innovative treatments for autoimmune diseases such as ITP.